Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $30.1 million.

  • Stoke Therapeutics' Accumulated Expenses rose 90.85% to $30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year increase of 90.85%. This contributed to the annual value of $18.6 million for FY2024, which is 34.40% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Accumulated Expenses is $30.1 million, which was up 17.48% from $25.6 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Accumulated Expenses ranged from a high of $30.1 million in Q3 2025 and a low of $11.1 million during Q1 2022.
  • Its 3-year average for Accumulated Expenses is $17.7 million, with a median of $14.5 million in 2024.
  • Per our database at Business Quant, Stoke Therapeutics' Accumulated Expenses declined by 12.27% in 2023 and then skyrocketed by 93.60% in 2025.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Accumulated Expenses stood at $15.7 million in 2022, then dropped by 12.27% to $13.8 million in 2023, then surged by 34.40% to $18.6 million in 2024, then surged by 90.85% to $30.1 million in 2025.
  • Its last three reported values are $30.1 million in Q3 2025, $25.6 million for Q2 2025, and $24.3 million during Q1 2025.